<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102804</url>
  </required_header>
  <id_info>
    <org_study_id>5122</org_study_id>
    <secondary_id>H3E-MC-JMEN</secondary_id>
    <nct_id>NCT00102804</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized Phase 3, double-blind study of maintenance pemetrexed plus best
      supportive care versus placebo plus best supportive care in NSCLC. Participants must have
      received 1 of 6 induction regimens for 4 cycles and did not have progressive disease prior to
      randomization (enrollment) into this trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Time</measure>
    <time_frame>Randomization to measured PD or death from any cause (up to 41 months)</time_frame>
    <description>PFS time was the elapsed time from the date of randomization to the first date of objective progression of disease or death from any cause. PFS was censored at the date of the participant's last tumor assessment for participants who were not known to have died or to have PD as of the data-inclusion cut-off date for analysis. PD, defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0), was at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Time</measure>
    <time_frame>Randomization to date of death from any cause (up to 41 months)</time_frame>
    <description>OS time was the elapsed time from the date of randomization to the date of death from any cause. OS was censored at the last date of contact for participants who were not known to have died as of the data-inclusion cut-off date for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Objective Progressive Disease (TPD)</measure>
    <time_frame>Randomization to measured PD (up to 41 months)</time_frame>
    <description>TPD was the elapsed time from the date of randomization to the first date of objective PD. TPD was censored at the date of the participant's last tumor assessment for participants who were not known to have PD as of the data-inclusion cut-off date for analysis or who died without objective PD. PD, defined using RECIST v1.0, was at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Worsening of Symptoms (TWS)</measure>
    <time_frame>Randomization to worsening of each LCSS item (up to 39 months)</time_frame>
    <description>TWS was the elapsed time from the date of randomization to the first date of worsening [defined as a 15-millimeter (mm) increase from baseline based on a 100-mm scale] of each symptom and summary item in the Lung Cancer Symptom Scale (LCSS). The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant (pt) responses to each item were measured using visual analogue scales (VAS) from 0 (for best outcome) to 100 (for worst outcome). TWS was censored at the date of the last LCSS assessment for pts who were not known to have LCSS worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate)</measure>
    <time_frame>Baseline to measured PD (up to 41 months)</time_frame>
    <description>Response was defined using RECIST v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined either A) at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or B) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more nontarget lesions. In either case, no new lesions may have appeared. The percentage of participants with CR or PR=(Number of participants with CR or PR)/(Number of participants assessed)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline to study completion (up to 41 Months)</time_frame>
    <description>Clinically significant events were defined as serious adverse events (SAEs) and other non-serious AEs regardless of causality. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS</measure>
    <time_frame>Baseline through 30 days post discontinuation of study treatment (up to 39 Months)</time_frame>
    <description>The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using VAS from 0 (for best outcome) to 100 (for worst outcome). The average symptom burden index (ASBI) was the mean of the 6 symptom-specific items. The LCSS total score was the mean of the 9 items.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">663</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pemetrexed and Best Supportive Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Best Supportive Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 milligrams per square meter (mg/m^2), intravenous (IV) administration, every (q) 21 days, until disease progression</description>
    <arm_group_label>Pemetrexed and Best Supportive Care</arm_group_label>
    <other_name>LY231514</other_name>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV administration, q 21 days</description>
    <arm_group_label>Placebo and Best Supportive Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
    <arm_group_label>Pemetrexed and Best Supportive Care</arm_group_label>
    <arm_group_label>Placebo and Best Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of NSCLC Stage IIIB (with pleural effusion and/or
             positive supraclavicular lymph nodes) or Stage IV prior to induction therapy.

          -  Participants must have had 1 of the following induction therapies for treatment for
             Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or IV
             NSCLC: Gemcitabine plus carboplatin, paclitaxel plus carboplatin, or docetaxel plus
             carboplatin, gemcitabine plus cisplatin, paclitaxel plus cisplatin or docetaxel plus
             cisplatin.

          -  Participants must have received only 1 chemotherapeutic doublet lasting precisely 4
             cycles.

          -  Induction regimens must be based on 21-day cycles.

          -  Documented evidence of a tumor response of complete response (CR), partial response
             (PR), or stable disease (SD). Tumor assessment must occur between Cycle 4 (Day 1) of
             induction therapy and the date of randomization. This response does not have to be
             confirmed in order for the participant to be randomized. Positron emission tomography
             (PET) scans and ultrasounds may not be used for lesion measurements for response
             determination.

        Exclusion Criteria:

          -  With the exception of those chemotherapies listed as inclusion criterion, participants
             will not be included if they have received prior systemic anticancer therapy
             (including adjuvant early-stage treatment for NSCLC) or any systemic treatment for any
             other cancer.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Inability to comply with protocol or study procedures.

          -  A serious concomitant systemic disorder that would compromise the participant's
             ability to complete the study.

          -  A serious cardiac condition, such as myocardial infarction within 6 months, angina, or
             heart disease, as defined by the New York Heart Association Class III or IV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ashford</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>VIC 3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ijui</city>
        <zip>98700 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01277-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dalian</city>
        <zip>116023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ji Nan</city>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nan Jing</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamm</city>
        <zip>59071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chania</city>
        <zip>73300</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mosdos</city>
        <zip>7257</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szombathely</city>
        <zip>H-9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Banglagore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jaipur</city>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mumbai</city>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>P.O Ernakulam</city>
        <zip>682304</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trivandrum</city>
        <zip>695 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bari</city>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Livorno</city>
        <zip>57128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Messina</city>
        <zip>98122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zwolle</city>
        <zip>80211 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>3400</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oradea</city>
        <zip>3700</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alcoi</city>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Matar√≥</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2005</study_first_submitted>
  <study_first_submitted_qc>February 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2005</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>December 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2014</results_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who signed the informed consent form (ICF) and completed the randomized process are presented in the participant flow by the treatment arm to which they were randomized. Participants who did not sign the ICF or complete the randomization process were removed from the database and excluded from all analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pemetrexed and BSC</title>
          <description>Pemetrexed: 500 milligrams per square meter (mg/m^2), intravenous (IV) administration, every (q) 21 days, until disease progression.
Best Supportive Care (BSC): Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
        </group>
        <group group_id="P2">
          <title>Placebo and BSC</title>
          <description>Placebo: IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="434"/>
                <participants group_id="P2" count="222">Four participants randomized to placebo received pemetrexed.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease (PD)</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrollment Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Satisfactory Response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alive, Receiving Treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Pemetrexed and BSC</title>
          <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
        </group>
        <group group_id="B2">
          <title>Placebo and BSC</title>
          <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="441"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="663"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" lower_limit="54.3" upper_limit="67.5"/>
                    <measurement group_id="B2" value="60.4" lower_limit="53.8" upper_limit="67.0"/>
                    <measurement group_id="B3" value="60.6" lower_limit="54.1" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="322"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Aboriginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) Time</title>
        <description>PFS time was the elapsed time from the date of randomization to the first date of objective progression of disease or death from any cause. PFS was censored at the date of the participant‚Äôs last tumor assessment for participants who were not known to have died or to have PD as of the data-inclusion cut-off date for analysis. PD, defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0), was at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.</description>
        <time_frame>Randomization to measured PD or death from any cause (up to 41 months)</time_frame>
        <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 123, 36 participants in the pemetrexed and placebo treatment arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed and BSC</title>
            <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and BSC</title>
            <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Time</title>
          <description>PFS time was the elapsed time from the date of randomization to the first date of objective progression of disease or death from any cause. PFS was censored at the date of the participant‚Äôs last tumor assessment for participants who were not known to have died or to have PD as of the data-inclusion cut-off date for analysis. PD, defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0), was at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.</description>
          <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 123, 36 participants in the pemetrexed and placebo treatment arms, respectively.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" lower_limit="4.07" upper_limit="4.73"/>
                    <measurement group_id="O2" value="2.60" lower_limit="1.68" upper_limit="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Time</title>
        <description>OS time was the elapsed time from the date of randomization to the date of death from any cause. OS was censored at the last date of contact for participants who were not known to have died as of the data-inclusion cut-off date for analysis.</description>
        <time_frame>Randomization to date of death from any cause (up to 41 months)</time_frame>
        <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 138, 48 participants in the pemetrexed and placebo treatment arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed and BSC</title>
            <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and BSC</title>
            <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Time</title>
          <description>OS time was the elapsed time from the date of randomization to the date of death from any cause. OS was censored at the last date of contact for participants who were not known to have died as of the data-inclusion cut-off date for analysis.</description>
          <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 138, 48 participants in the pemetrexed and placebo treatment arms, respectively.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.37" lower_limit="11.93" upper_limit="15.87"/>
                    <measurement group_id="O2" value="10.58" lower_limit="8.74" upper_limit="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Objective Progressive Disease (TPD)</title>
        <description>TPD was the elapsed time from the date of randomization to the first date of objective PD. TPD was censored at the date of the participant‚Äôs last tumor assessment for participants who were not known to have PD as of the data-inclusion cut-off date for analysis or who died without objective PD. PD, defined using RECIST v1.0, was at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.</description>
        <time_frame>Randomization to measured PD (up to 41 months)</time_frame>
        <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 145, 40 participants in the pemetrexed and placebo treatment arms, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed and BSC</title>
            <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and BSC</title>
            <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Objective Progressive Disease (TPD)</title>
          <description>TPD was the elapsed time from the date of randomization to the first date of objective PD. TPD was censored at the date of the participant‚Äôs last tumor assessment for participants who were not known to have PD as of the data-inclusion cut-off date for analysis or who died without objective PD. PD, defined using RECIST v1.0, was at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.</description>
          <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 145, 40 participants in the pemetrexed and placebo treatment arms, respectively.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" lower_limit="4.11" upper_limit="4.73"/>
                    <measurement group_id="O2" value="2.60" lower_limit="1.68" upper_limit="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Worsening of Symptoms (TWS)</title>
        <description>TWS was the elapsed time from the date of randomization to the first date of worsening [defined as a 15-millimeter (mm) increase from baseline based on a 100-mm scale] of each symptom and summary item in the Lung Cancer Symptom Scale (LCSS). The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant (pt) responses to each item were measured using visual analogue scales (VAS) from 0 (for best outcome) to 100 (for worst outcome). TWS was censored at the date of the last LCSS assessment for pts who were not known to have LCSS worsening.</description>
        <time_frame>Randomization to worsening of each LCSS item (up to 39 months)</time_frame>
        <population>Pts who signed ICF and completed randomization, according to treatment randomized. Pts censored: Loss of appetite 236,140; fatigue 237,130; cough 274,146; dyspnea 271,143, hemoptysis 404,198; pain 271,135; symptom distress 247,141; interference with activity level 267,141, global quality of life 262,137 pts in pemetrexed, placebo arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed and BSC</title>
            <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and BSC</title>
            <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Worsening of Symptoms (TWS)</title>
          <description>TWS was the elapsed time from the date of randomization to the first date of worsening [defined as a 15-millimeter (mm) increase from baseline based on a 100-mm scale] of each symptom and summary item in the Lung Cancer Symptom Scale (LCSS). The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant (pt) responses to each item were measured using visual analogue scales (VAS) from 0 (for best outcome) to 100 (for worst outcome). TWS was censored at the date of the last LCSS assessment for pts who were not known to have LCSS worsening.</description>
          <population>Pts who signed ICF and completed randomization, according to treatment randomized. Pts censored: Loss of appetite 236,140; fatigue 237,130; cough 274,146; dyspnea 271,143, hemoptysis 404,198; pain 271,135; symptom distress 247,141; interference with activity level 267,141, global quality of life 262,137 pts in pemetrexed, placebo arm, respectively.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" lower_limit="2.86" upper_limit="4.44"/>
                    <measurement group_id="O2" value="4.40" lower_limit="2.96" upper_limit="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" lower_limit="2.63" upper_limit="5.29"/>
                    <measurement group_id="O2" value="3.09" lower_limit="2.43" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" lower_limit="4.21" upper_limit="7.82"/>
                    <measurement group_id="O2" value="4.67" lower_limit="3.06" upper_limit="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" lower_limit="4.21" upper_limit="10.87"/>
                    <measurement group_id="O2" value="4.40" lower_limit="2.83" upper_limit="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoptysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median (95% confidence interval) TWS for hemoptysis was not calculated due to the high level of censoring.</measurement>
                    <measurement group_id="O2" value="NA">Median (95% confidence interval) TWS for hemoptysis was not calculated due to the high level of censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" lower_limit="4.57" upper_limit="9.56"/>
                    <measurement group_id="O2" value="4.63" lower_limit="3.32" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic distress</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" lower_limit="3.58" upper_limit="5.55"/>
                    <measurement group_id="O2" value="3.78" lower_limit="2.99" upper_limit="18.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interference with activity level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.51" lower_limit="4.34" upper_limit="8.18"/>
                    <measurement group_id="O2" value="3.98" lower_limit="2.83" upper_limit="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global quality of life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" lower_limit="4.37" upper_limit="8.41"/>
                    <measurement group_id="O2" value="3.71" lower_limit="2.99" upper_limit="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate)</title>
        <description>Response was defined using RECIST v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined either A) at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or B) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more nontarget lesions. In either case, no new lesions may have appeared. The percentage of participants with CR or PR=(Number of participants with CR or PR)/(Number of participants assessed)*100.</description>
        <time_frame>Baseline to measured PD (up to 41 months)</time_frame>
        <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed and BSC</title>
            <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and BSC</title>
            <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate)</title>
          <description>Response was defined using RECIST v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined either A) at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or B) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more nontarget lesions. In either case, no new lesions may have appeared. The percentage of participants with CR or PR=(Number of participants with CR or PR)/(Number of participants assessed)*100.</description>
          <population>Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>Clinically significant events were defined as serious adverse events (SAEs) and other non-serious AEs regardless of causality. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline to study completion (up to 41 Months)</time_frame>
        <population>Participants who signed the ICF, completed the randomized process and received at least 1 dose of study drug are reported according to the treatment to which they were received.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed and BSC</title>
            <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and BSC</title>
            <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>Clinically significant events were defined as serious adverse events (SAEs) and other non-serious AEs regardless of causality. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.</description>
          <population>Participants who signed the ICF, completed the randomized process and received at least 1 dose of study drug are reported according to the treatment to which they were received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Non-Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS</title>
        <description>The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using VAS from 0 (for best outcome) to 100 (for worst outcome). The average symptom burden index (ASBI) was the mean of the 6 symptom-specific items. The LCSS total score was the mean of the 9 items.</description>
        <time_frame>Baseline through 30 days post discontinuation of study treatment (up to 39 Months)</time_frame>
        <population>Participants who signed the ICF, completed the randomization process, had LCSS data at baseline and at least once postdose are reported according to the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed and BSC</title>
            <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and BSC</title>
            <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS</title>
          <description>The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using VAS from 0 (for best outcome) to 100 (for worst outcome). The average symptom burden index (ASBI) was the mean of the 6 symptom-specific items. The LCSS total score was the mean of the 9 items.</description>
          <population>Participants who signed the ICF, completed the randomization process, had LCSS data at baseline and at least once postdose are reported according to the treatment arm to which they were randomized.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Loss of appetite (n=403, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="25.90"/>
                    <measurement group_id="O2" value="10.6" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=403, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="27.10"/>
                    <measurement group_id="O2" value="10.4" spread="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough (n=402, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="20.09"/>
                    <measurement group_id="O2" value="6.7" spread="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (n=400, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="22.50"/>
                    <measurement group_id="O2" value="5.4" spread="20.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (n=401, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="20.96"/>
                    <measurement group_id="O2" value="4.3" spread="21.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoptysis (n=402, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="9.41"/>
                    <measurement group_id="O2" value="2.1" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom distress (n=401, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="21.13"/>
                    <measurement group_id="O2" value="8.2" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interference with activity level (n=400, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="27.08"/>
                    <measurement group_id="O2" value="9.3" spread="25.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global quality of life (n=401, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="24.94"/>
                    <measurement group_id="O2" value="10.5" spread="22.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASBI (n=392, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="12.34"/>
                    <measurement group_id="O2" value="3.8" spread="13.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total LCSS (n=388, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" spread="12.76"/>
                    <measurement group_id="O2" value="4.04" spread="13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants are reported under the treatment to which they received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pemetrexed and BSC</title>
          <description>Pemetrexed: 500 mg/m^2, IV administration, q 21 days, until disease progression.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
        </group>
        <group group_id="E2">
          <title>Placebo and BSC</title>
          <description>Placebo: IV administration, q 21 days.
BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="438"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Superior vena caval occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="386" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="97" subjects_affected="65" subjects_at_risk="438"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="64" subjects_affected="25" subjects_at_risk="438"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="66" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="17" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Keratoconjunctivitis sicca</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="438"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="85" subjects_affected="59" subjects_at_risk="438"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="88" subjects_affected="52" subjects_at_risk="438"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="438"/>
                <counts group_id="E2" events="21" subjects_affected="6" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="209" subjects_affected="102" subjects_at_risk="438"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tongue black hairy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tongue coated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="88" subjects_affected="56" subjects_at_risk="438"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="48" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="14" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="67" subjects_affected="44" subjects_at_risk="438"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="227" subjects_affected="145" subjects_at_risk="438"/>
                <counts group_id="E2" events="63" subjects_affected="49" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="438"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="78" subjects_affected="56" subjects_at_risk="438"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Visceral oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="87" subjects_affected="60" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="63" subjects_affected="52" subjects_at_risk="438"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood fibrinogen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Granulocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Granulocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="19" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Platelet count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Red blood cell microcytes present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sensory level</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Total bile acids increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Troponin t</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Alcohol intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="238" subjects_affected="124" subjects_at_risk="438"/>
                <counts group_id="E2" events="43" subjects_affected="40" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="438"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="438"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="438"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="438"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Angiolipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="39" subjects_affected="34" subjects_at_risk="438"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="62" subjects_affected="51" subjects_at_risk="438"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hemicephalalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="438"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="438"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="438"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="118" subjects_affected="95" subjects_at_risk="438"/>
                <counts group_id="E2" events="50" subjects_affected="47" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="118" subjects_affected="98" subjects_at_risk="438"/>
                <counts group_id="E2" events="45" subjects_affected="43" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="438"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="438"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="81" subjects_affected="62" subjects_at_risk="438"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumatic compression therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Tumour excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="438"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Superior vena caval occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Four participants (pts) assigned to placebo received pemetrexed; pts analyzed for efficacy as randomized. Three treated pts did not sign ICF, 1 treated pt signed ICF but did not complete entire randomization process; pts excluded from all analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

